Towards Healthcare Research & Consulting

Autoimmune Disease Diagnostics Market Growth, Innovations and Market Size Forecast 2035

The global autoimmune disease diagnostics market size was estimated at USD 6.11 billion in 2025 and is predicted to increase from USD 6.49 billion in 2026 to approximately USD 10.5 billion by 2035, expanding at a CAGR of 6.22% from 2026 to 2035. Our senior research analyst, Payal Rabade, with her extensive experience in healthcare, indicates exponential market growth due to the rising prevalence of autoimmune disorders, increasing demand for early and accurate diagnosis, growing awareness of disease symptoms, and advancements in biomarker-based testing and molecular diagnostic technologies. 

Last updated 30 September 2026   |   Primary source: Towards Healthcare, report 5723   |   Derived values are labelled

The global autoimmune disease diagnostics market size is calculated at USD 6.11 in 2025, grew to USD 6.49 billion in 2026, and is projected to reach around USD 10.5 billion by 2034. The market is expanding at a CAGR of 6.22% between 2025 and 2034.

 

Autoimmune Disease Diagnostics Market Size 2024 - 2034

The global autoimmune disease diagnostics market is driven by several factors, including increasing instances, rising awareness among patients and healthcare professionals, along with breakthroughs in novel technologies in molecular diagnostics, biomarker discovery, and personalized medicine are enhancing accuracy and efficiency in diagnosis. Moreover, the growing opportunities in the market are the development of groundbreaking biomarkers, molecular diagnostics and tests, evolving personalized medicine approaches, and the development of integrated digital health technologies.

Key Takeaways

  • The autoimmune disease diagnostics market will likely exceed USD 6.11 billion by 2025.
  • Valuation is projected to hit USD 10.5 billion by 2034.
  • Estimated to grow at a CAGR of 6.22% starting from 2025 to 2034.
  • North America dominated the market share by 47% in 2025.
  • Asia Pacific is expected to be the fastest-growing region in the upcoming years.
  • By type, the localized segment held the largest revenue share of the market in 2025.
  • By type, the systemic disorders segment is expected to grow at the fastest CAGR during the forecast period.
  • By product, the consumables & assays segment led the autoimmune disease diagnostics market in 2025.
  • By product, the instruments segment is expected to grow significantly over the projected period.
  • By test type, the antinuclear antibody tests segment held the dominating revenue share of the market in 2025.
  • By test type, the autoantibody tests segment is expected to be the fastest-growing segment in the upcoming years.
  • By end use, the hospital segment led the market in 2025.
  • By end use, the diagnostic centers segment is expected to grow at the fastest CAGR during the projected timeframe.

Market Overview

Autoimmune diseases are conditions in which the immune system of the body falsely attacks its healthy tissues and cells. Basically, diagnostics used in these diseases are involved in the identification and assessment of conditions. Globally, increasing the number of autoimmune cases, technological advancements, and growing awareness are impacting the growth of the autoimmune disease diagnostics market. Moreover, breakthroughs in technologies like nanotechnology and genomics are broadly supporting research in autoimmune diseases. These diagnostics are highly employed in the development of personalized medicine, anticipating disease progression, and drug discovery.

What are the Trends in the Autoimmune Disease Diagnostics Market?

  • In February 2025, Allogene Therapeutics, Inc., a clinical-stage biotechnology company, entered into a partnership with Foresight Diagnostics, Inc., to develop Foresight’s minimal residual disease (MRD) assay as a companion diagnostic to determine patients with large B-cell lymphoma (LBCL) for treatment with cemacabtagene ansegedleucel (cema-cel). (Source - Finance)
  • In September 2024, Carisma Therapeutics Inc., a clinical-stage biopharmaceutical company, expanded its partnership with Moderna, Inc., an American pharmaceutical and biotechnology company, to comprise the nomination of two targets for the treatment of autoimmune diseases. (Source - PR Newswire)
  • In October 2024, there is the Accelerating Medicines Partnership (AMP) Program is a public-private partnership between the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), multiple biopharmaceutical and life science companies, and nonprofit organizations to revolutionize the recent model for evolving novel diagnostics and treatments by co-operatively detecting and confirming favourable biological targets for therapeutics. (Source - NIA)

How is AI Powering the Autoimmune Disease Diagnostics Market?

In the expansion of the market, AI has a major role as it assists in the analysis of a huge volume of datasets to detect patterns and robust markers, supporting prior detection and optimizing diagnostic accuracy. Also, its algorithms enable examination of medical images and clinical data, providing insights that might be skipped by conventional approaches, resulting in more timely and precise diagnoses.

For instance,

  • In May 2025, WellTheory, a digital health company enlightening autoimmune disease, invested $5 million with collaborative support from Samsung Next, Opal Ventures, and Up2 Fund, as well as existing investors Accel, OVO Fund, and BoxGroup. The company has raised $12 million. Along with this, they launched two innovative AI tools called Care Scribe and Care Hub. (Source - MedCity News)

Market Dynamics

Driver

Growing Prevalence and Technological Advancements

Around the world, there is a rise in instances related to autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, and lupus, which require highly precise diagnostic tools are propelling the growth of the autoimmune disease diagnostics market. Moreover, consistent optimization in diagnostic technologies, like biomarker identification, genetic testing, and imaging modalities, is improving the efficiency and accuracy level in technological breakthroughs.

Restraint

Limitations on Spending and Standardized Diagnostic Criteria

The challenges involved in the market growth are the rising expenses of specialized tests for autoimmune diseases, including those for antinuclear antibodies (ANAs) or specific autoantibodies, which are crucial, ultimately restricting access for patients and healthcare facilities. Although autoimmune diseases are complex, they show difficult symptoms, which raises the challenge of developing globally accepted diagnostic criteria.

Opportunity

Escalating Novel Technologies and Therapies

The autoimmune disease diagnostics market, experiencing many rising opportunities such as, "Omics" research (genomics, proteomics, metabolomics) which enables a complete understanding of the molecular alterations linked with autoimmune diseases, nanotechnology supports in drug delivery, targeting specific cells and tissues, and for designing new diagnostic tools, like biosensors. As well as therapies like synthetic receptor-based cell therapies, targeting and removing autoreactive cells in autoimmune diseases, are also proposing an innovative opportunity in the respective market.

Autoimmune Diagnostics Market Advances Through Precision Testing and Early Detection

The autoimmune disease diagnostics market comprises diagnostic tests and technologies used to identify autoimmune disorders by detecting disease-specific antibodies, biomarkers, and other immune-system abnormalities. The market is growing due to the increasing prevalence of autoimmune conditions and rising demand for timely, accurate diagnosis to support effective disease management. A major trend is the adoption of multiplex testing, biomarker-based assays, and personalized diagnostic approaches that enable more targeted disease identification. Technological advancements in immunoassays, molecular diagnostics, next-generation sequencing, and artificial intelligence are improving diagnostic accuracy and laboratory efficiency. Future opportunities are emerging from companion diagnostics, digital health integration, and the discovery of novel biomarkers for complex autoimmune disorders. Additionally, growing healthcare awareness, improved access to specialized testing, increasing research into autoimmune diseases, and expanding diagnostic infrastructure are driving market development across emerging and developed healthcare markets.

Key Metrics and Overview

Metric Details
Market Size in 2025 USD 6.11 Billion
Projected Market Size in 2034 USD 10.5 Billion
CAGR (2025 - 2034) 6.22%
Leading Region North America share by 47%
Market Segmentation By Type, By Product, By Test Type, By End Use, By Region
Top Key Players Abbott Laboratories, Thermo Fisher Scientific, Siemens AG, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Quest Diagnostics, Hologic, Danaher, Inova Diagnostics., EUROIMMUN Medizinische Labordiagnostika AG, Nova Diagnostics Pte Ltd., BIOMÉRIEUX, Hemagen Diagnostics, Inc.

Segmental Insights

What Made the Localized Segment Dominate the Market in 2025?

By type, the localized segment held the major revenue share of the autoimmune disease diagnostics market in 2025.  Primarily, this segment is driven by factors like accelerating cases of localized autoimmune diseases, technological developments, and boosting awareness about diseases and treatments as they enhance the accuracy and wider application in clinical settings.

By type, the systemic disorders segment is expected to grow fastest during the forecast period. The propelling factors, along with rising prevalences, are raised awareness in healthcare professionals and patients related to diseases that demand for as soon as possible diagnosis and intervention. However, the increasing adoption of personalized medicine processes and ongoing R&D address mechanisms results in innovative diagnostic and therapeutic strategies.

Which Type of Product Held the Major Revenue Share of the Autoimmune Disease Diagnostics Market in 2025?

By product, the consumables & assays segment led the market in 2024, as the rising demand for specific assays and tests, including antinuclear antibody (ANA) tests and rheumatoid factor assays, is significantly fueling the market growth. Besides this, new emerging technologies such as multiplex assays and biosensors, and the expansion of clinical laboratories and diagnostic centers, require a higher count of diagnostic tests, which consequently results in the growth of the consumables and assays segment.

By product, the instruments segment is expected to grow fastest in the projected period. Around the world, the increasing demand for rapid, precise, and automated approaches is propelling the need for advanced instruments is a critical factor for the expansion of the segment. Also, these kinds of instruments assist in early-stage detection of autoimmune diseases, which enhances their adoption and patient outcomes.

How did the Antinuclear Antibody Tests Segment Lead the Market in 2025?

By test type, the antinuclear antibody tests segment held the largest share is contributing to its dominance in the market. These tests are enabling early and accurate diagnosis, which is significantly driving the expansion of this segment in the autoimmune disease diagnostics market. Along with this, boosting technological breakthroughs of more sensitive and particular ANA test approaches, such as ELISA, IFA, and multiplex assays, optimizes the reliability and accuracy of diagnosis.

By test type, the autoantibody tests segment is expected to be the fastest-growing during the forecast period. Mainly, driven by the accelerating demand for accurate diagnosis and management of autoimmune conditions, diagnostic technologies developments, and the growing adoption of personalized medicine. This test assists in prior disease detection, tracking disease progression, and assessing the likelihood of developing specific autoimmune conditions.

Why did the Hospital Segment Hold a Significant Share of the Market in 2025?

By end use, the hospital segment dominated the autoimmune disease diagnostics market in 2024. As hospitals possess sophisticated resources and skilled professionals to cater to complex diagnostic methods, and provide specialized care for autoimmune diseases. As well as growing healthcare expenses, especially in developed regions, enable broader access to advanced diagnostic technologies, which are available in different hospitals.

By end use, the diagnostic centers segment is expected to grow at the fastest CAGR in the upcoming years. Majorly, these diagnostic centers allow innovative technologies such as biomarker identification, genetic testing, and imaging modalities, which optimize the accuracy and effectiveness of autoimmune disease detection. Nowadays, rising investments in the development of new centers, aimed at enhancing diagnostic capabilities and providing proper appointments, create chances for autoimmune disease diagnostics providers.

Regional Insights

What Made North America Dominate the Market in 2025?

North America held the largest revenue share of the market share by 47%  in 2025. Contributing factors are increasing instances, along with a broad hub for R&D in the respective sector, leading to the development of novel diagnostic tools and techniques, which enhance precise and efficient diagnosis. Also, they have a well-developed healthcare infrastructure, possessing advanced diagnostic provisions and a complex healthcare professional.

The U.S. Autoimmune Disease Diagnostics Market Trends

In the US, the rising population with awareness and education efforts has led to a higher recognition of autoimmune diseases, encouraging for early diagnosis and treatment in individuals. Also, the novel is increasing diagnostic tools and techniques, including molecular diagnostics, next-generation sequencing, and immunodiagnostics, which are boosting the accuracy and efficiency of autoimmune disease detection.

For instance,

  • In February 2025, Biocon Biologics, a subsidiary of Biocon, launched YESINTEK (ustekinumab-kfce), a biosimilar option to Stelara (ustekinumab) in the US market. (Source - Business Standard)

The Canada Autoimmune Disease Diagnostics Market Trends

The market is highly influenced by the increased expenditure on healthcare in Canada, like diagnostic testing, which is a vital factor in driving the market growth. Although initiatives by the government and their policies that support reimbursement for diagnostic tests for autoimmune diseases, which boost the application of diagnostics and ultimately result the market growth.

Rising Cases and Escalating Healthcare Infrastructure are Driving Asia Pacific

In ASAP, the autoimmune disease diagnostics market is driven by an accelerated population, with instances related to autoimmune diseases experiencing raised awareness among medical professionals about early detection of disease, and a well-established, rising healthcare infrastructure with sophisticated diagnostic facilities is expanding the market.

The China Autoimmune Disease Diagnostics Market Trends

China has been facing a wide range of novel and accelerated advancements in diagnostic technologies like antinuclear antibody tests and autoantibody tests, which are highly utilized in rising prevalences of autoimmune conditions.

The India Autoimmune Disease Diagnostics Market Trends

In India, a major population is focusing on the consumption of personalized medicine, which enhances the efficient outcomes with raised accuracy for individual characteristics. Over this, the market is experiencing significant growth due to a rising shift towards early diagnosis of diseases in the increasing instances, as well, with robust and rapid diagnostic tests.

For instance,

  • In September 2023, NeoDx Biotech Labs, a Bengaluru-based startup, launched a Real-time PCR-technology-based in vitro diagnostic (IVD) kit for autoimmune conditions like Ankylosing Spondylitis, which empowers healthcare services to optimize their testing facilities. (Source - BioSpectrum)

Increasing Geriatric Population and Government Encouragement are Driving Europe

Europe is anticipating significant market growth impelled by the rising geriatric population linked with autoimmune diseases, which requires more accurate diagnostics for enhanced outcomes in the same. As well as, the European government is encouraging a focus on developed healthcare infrastructure and assisting R&D, which are playing a crucial role.

For instance,

  • In January 2025, Celltrion, an innovator in the biosimilar space, launched 'Steqeyma' (ingredient name ustekinumab), a biosimilar for the treatment of autoimmune diseases, in five European countries: Germany, Spain, the United Kingdom, Italy, and France. (Source - CHOSUNBIZ EN)

The Germany Autoimmune Disease Diagnostics Market Trends

The growing prevalence of raised awareness in patients is demanding advanced diagnostic tests, which is a major driver in the market expansion. Also, the increasing adoption of personalized medicine and technological advancements in the rising healthcare infrastructure are propelling the market growth.

The UK Autoimmune Disease Diagnostics Market Trends

The UK has been experiencing significant market growth, driven by the rising adoption of technological advancements like biomarker identification, genetic testing, and imaging modalities are expanding their market over the globe. Due to developments, patients are also taking steps towards early disease detection to improve the treatment for themselves.

Latin America Expands with Growing Demand for Autoimmune Disease Testing

Latin America’s autoimmune disease diagnostic market is expanding due to increasing awareness of autoimmune disorders, improving access to specialized healthcare, and rising demand for early and accurate diagnosis. Growing investments in healthcare infrastructure and laboratory capabilities are supporting wider adoption of advanced immunoassays and biomarker-based testing. Additionally, the expansion of private diagnostic networks and increasing research activities are creating opportunities for autoimmune disease testing across the region.

Brazil Expands Through Advanced Autoimmune Testing

Brazil’s autoimmune disease diagnostics market is expanding due to increasing awareness of autoimmune disorders, growing demand for early diagnosis, and improved access to specialized healthcare services. Expansion of diagnostic laboratories and adoption of advanced immunoassays and biomarker-based testing are supporting market development. Additionally. Brazil’s large patient population and growing healthcare investments create opportunities for diagnostic providers.

Argentina Advances in Autoimmune Disease Diagnostics

Argentina’s autoimmune disease diagnostics market is expanding due to rising awareness of autoimmune disorders, increasing demand for early diagnosis, and improved access to specialized testing. Growing laboratory capabilities and adoption of advanced immunoassays are supporting diagnostic accuracy. Additionally, expanding healthcare infrastructure and research activities are creating opportunities for innovation in autoimmune diagnostic solutions across the country.

Middle East and Africa Expands Through Improved Diagnostic Access

The Middle East and Africa autoimmune disease diagnostics market is expanding due to increasing awareness, improving healthcare infrastructure, and growing access to specialized diagnostic services. Rising healthcare investments, laboratory modernization, and earlier and more accurate detection of autoimmune disorders across the region.

South Africa Advances Through Growing Diagnostic Capabilities

South Africa’s autoimmune disease diagnostics market is expanding due to increasing awareness of autoimmune disorders, improved access to specialized healthcare, and modernization of diagnostics laboratories. Growing healthcare investments and adoption of advanced immunoassays and biomarkers-based testing are supporting earlier disease detection, while expanding research activities are creating opportunities for innovative diagnostic solutions.

UAE Grows Through Advanced Healthcare and Diagnostic Infrastructure

The UAE’s autoimmune disease diagnostics market is growing due to increasing healthcare investments, rising awareness of autoimmune disorders, and expanding access to specialized medical services. The modernization of diagnostic laboratories and adoption of advanced immunoassays and molecular testing are supporting earlier and more accurate detection. Additionally, the UAE’s focus on healthcare technology and medical innovation is creating opportunities for advanced diagnostic solutions.

Top Companies in the Autoimmune Disease Diagnostics Market

Autoimmune Disease Diagnostics Market Companies

Latest Announcements by Industry Leaders

  • In January 2025, Quanterix Corporation, a company powering scientific discovery through ultra-sensitive biomarker detection, announced an agreement with Akoya Biosciences, the Spatial Biology Company®, under which Quanterix will acquire Akoya in an all-stock transaction and will develop the foremost integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers. Masoud Toloue, PhD, Chief Executive Officer of Quanterix, commented that this transaction enhances their success by generating the first platform that assists researchers and clinicians in tracking disease progression from tissue to blood. (Source - Businesswire)
  • In January 2025, OMNY Health, the global healthcare ecosystem for compliant real-world data insights at scale, and Scipher Medicine, possessing the world’s largest immunology clinico-transcriptomics data set, announced a partnership to advance precision medicine powers for immunology.  Dr. Mitesh Rao, Founder and CEO of OMNY Health, stated that they are committed to their faith that increasingly targeted therapies and treatments for autoimmune conditions are the key to enhancing healthcare outcomes. (Source - Businesswire)

Recent Developments in the Autoimmune Disease Diagnostics Market

  • In April 2025, Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic products, launched its first molecular diagnostic product to optimize the prognosis of multiple myeloma. (Source - Businesswire)
  • In August 2024, Progentec Diagnostics, Inc., a developer in diagnostic and digital technologies for autoimmune diseases, launched CareMGMT™, an innovative app that enables individuals to take control of their autoimmune health journey. (Source - PR Newswire)

Segments Covered in the Report

By Type

  • Systemic autoimmune disease diagnostics
    • Rheumatoid arthritis
    • Ankylosing spondylitis
    • Systemic lupus erythematosus (SLE)
    • Others
  • Localized autoimmune disease diagnostics
    • Multiple sclerosis
    • Type 1 diabetes
    • Hashimoto's Thyroiditis
    • Idiopathic thrombocytopenic purpura
    • Others

By Product

  • Instruments
  • Consumables and Assays

By Test Type

  • Antinuclear antibody tests
  • Autoantibody tests
  • C-reactive Protein (CRP)
  • Complete blood count (CBC)
  • Urinalysis
  • Others

By End Use

  • Hospitals
  • Diagnostic centers
  • Others

By Region

  • North America
    • U.S.
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA)
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait

FAQ

Finding : The autoimmune disease diagnostics market is projected to reach USD 10.5 billion by 2034, growing at a CAGR of 6.22% from 2024 to 2034.

Finding : North America is currently leading the autoimmune disease diagnostics market due to the rising cases and breakthroughs in technology developments.

Finding : The autoimmune disease diagnostics market includes five segments such as by type, by product, by test type, by end use, and by region.

Meet the Team

Payal Rabde

Payal Rabde

Principal Consultant

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde
Aditi Shivarkar

Aditi Shivarkar LinkedIn

Reviewed By

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar